This one has a reasonably settled answer, so here it is. Quarterly for the first year is convention rather than evidence, and it is defensible for a simple reason: it is roughly the interval over which HbA1c becomes informative again, since it reflects about three months of glycaemia. After the first year, and once doses are stable, annual is reasonable unless something specific is being followed.
I got a full panel before starting and a repeat at three months, and the second one is more useful than the first purely because I now have something to compare against.
What I actually want to know is how often to repeat it, because quarterly seems to be the convention and I cannot find the reasoning.
If the honest answer is that nobody knows, that is a useful answer and I would rather have it.
pete_manc_UK said:Quarterly for the first year is convention rather than evidence, and it is defensible for a simple reason: it is roughly the interval over which HbA1c…
pete_manc_UK has the substance of this right. The condition it depends on is worth stating. One addition: if the lab changes analytical platform between your draws, the comparison breaks and nobody tells you. It is worth asking when a value moves inexplicably.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsDataDave said:I got a full panel before starting and a repeat at three months, and the second one is more useful than the first purely because I now have something…
Same position here, arrived at the long way round. A defensible baseline is short: HbA1c and fasting glucose, a lipid panel with ApoB if you can get it, ALT and AST, creatinine with eGFR, TSH, ferritin and B12, and a full blood count. That set catches the things that change, the things that explain symptoms, and the things that alter the prescribing decision. Almost everything else on the long circulating lists is either invariant, uninterpretable without a specific question, or an incidental finding waiting to cause an unnecessary workup.
Clinical perspective, offered as context rather than as advice.
Shot day Monday report relevant to baseline bloodwork:
Week 23. Currently on 10mg. Down 79 lbs from starting weight of 291 lbs.
This week's observations: Appetite very well controlled, no cravings.
Labs due next week — looking forward to seeing the metabolic panel. I'll post results in the Lab Results section when they come in.